Eli Lilly Foundayo|5x Fewer Prescriptions Than Wegovy

The Pill That Should Have Changed Everything

Eli Lilly posted first-quarter revenue of $19.8 billion, up 56% year over year, and Wall Street raised its price targets to $1,425. The injection franchise was doing everything right — Mounjaro brought in $8.66 billion worldwide, more than doubling from the prior year, and Zepbound US sales rose 80% to $4.16 billion on pure volume gains even as realized prices fell. The bottleneck is not in the injectable drugs. It is in the oral pill that was supposed to extend the franchise to the millions of patients who will not take a shot.

Foundayo, Lilly's oral GLP-1 launched in April 2026, is generating 19,550 weekly prescriptions at week 13, and that number has fallen for three consecutive weeks from a peak of 21,648 at week 10. Novo Nordisk's Wegovy pill had more than 105,000 weekly prescriptions at the identical point after its launch. Jefferies projects $71 million in Foundayo's debut quarter against a Wall Street consensus near $130 million. The gap is not noise — it is a structural divergence between two oral drugs in the same category launched in the same market.

The question this creates for every Lilly holder is not whether the injection business is strong — it demonstrably is. The question is whether the momentum that doubled Mounjaro in one year can translate into an oral drug that patients and their doctors are still learning to trust. The injection franchise proved demand; the pill franchise has to prove the molecule is worth switching to, and the prescription data at week 13 says that proof is incomplete.

Why Foundayo Is Not Wegovy

The coverage gap is the first and most defensible explanation. CVS was the last of the three major pharmacy benefit managers to cover Foundayo, while Wegovy's oral version had full PBM coverage in its first week of launch. Without coverage, prescriptions do not flow regardless of efficacy, and Foundayo entered its critical early ramp with a disadvantage that Wegovy never faced.

But coverage explains only part of the gap. The deeper issue is molecule familiarity. Wegovy's pill is semaglutide — the same compound doctors have prescribed for years in Ozempic injections. Physicians who write it know the side-effect profile, the titration schedule, and the patient population that responds. Foundayo is a new compound with a new brand name, which means the entire prescriber education curve has to run before the drug reaches its natural volume. Oral Wegovy had a standing prescription base to convert; Foundayo has to build one from zero.

This is the buried assumption the bull case requires: that the trust clinicians have built with Mounjaro and Zepbound injection patients will automatically migrate to a new oral compound under a new brand. The prescription data at week 13 suggests prescribers are not treating Foundayo as a natural extension of the Lilly GLP-1 franchise — they are treating it as a separate drug that has to earn its place on its own evidence. That distinction matters more than the coverage timing, because coverage gaps close within months, but a new molecule's prescriber adoption curve runs for years.

The DMT Acquisition and What It Signals

On July 16, Lilly announced it would acquire AtaiBeckley for $6.75 per share in cash at close, plus up to $2.50 per share in contingent value rights tied to clinical and regulatory milestones. AtaiBeckley's lead asset, BPL-003, is a synthetic form of 5-MeO-DMT administered intranasally for treatment-resistant depression — a psychedelic compound that has FDA Breakthrough Therapy Designation and has initiated Phase 3 activities. The second program, VLS-01, is a buccal film formulation of DMT in an ongoing Phase 2b study.

The acquisition invites two competing readings. The first: Lilly's management has privately concluded that the oral GLP-1 market is harder to capture than the injection market, and is therefore diversifying into neuroscience to build a second growth platform. The second: the AtaiBeckley deal is a pure neuroscience bet that has nothing to do with GLP-1 positioning, and reading it as a signal about the oral pill ceiling imposes a strategic narrative the press release does not support. Both readings are live in the articles and neither is definitively closed.

What the bulls have not fully priced is the regulatory structure of the CVR. The $0.50-per-share milestone for BPL-003 requires both U.S. regulatory approval AND DEA rescheduling within five years of closing. Psychedelic compounds face an approval pathway that is not only clinical but political — DEA rescheduling depends on the administration and enforcement priorities in ways that drug efficacy alone cannot resolve. A Phase 3 success for BPL-003 does not guarantee the CVR pays; it guarantees a regulatory filing into a DEA that may move slowly regardless of the trial outcome.

For holders into the August earnings report, the single variable that most discriminates the bull thesis from a trap is not the analyst target — five upgrades from $1,273 to $1,425 are already in the price. The variable is Foundayo's weekly prescription trajectory in the IQVIA data published each week before the quarter closes. If Foundayo recovers toward the 60,000-range by mid-August, the coverage-timing explanation holds and the injection-franchise momentum story survives the oral challenge. If prescriptions stay near 20,000, the $130 million consensus estimate faces a cut and the gap between analyst targets and actual oral drug adoption becomes the story going into earnings. Holders watch the IQVIA weekly print; watchers enter only if that recovery is already visible. The DEA rescheduling risk on BPL-003 is a separate, longer-dated uncertainty — it does not resolve before August, but it narrows the multiple the acquisition justifies today.